Loading…
Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients
Angiogenesis is an essential process for the expansion of multiple myeloma (MM), in which many angiogenic factors participate. Endoglin (CD105) is a transforming growth factor‐β co‐receptor, being mainly expressed in angiogenic endothelial cells and has been used as a marker of tumor angiogenesis, h...
Saved in:
| Published in: | Hematological oncology 2013-12, Vol.31 (4), p.201-205 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3924-fe0bc4c6bca69776a7c7f8c486454e27d826bd4319bbe718bf94e1b940c08d2d3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3924-fe0bc4c6bca69776a7c7f8c486454e27d826bd4319bbe718bf94e1b940c08d2d3 |
| container_end_page | 205 |
| container_issue | 4 |
| container_start_page | 201 |
| container_title | Hematological oncology |
| container_volume | 31 |
| creator | Pappa, CA Alexandrakis, MG Boula, A Psarakis, FE Kolovou, A Bantouna, V Stavroulaki, E Tsirakis, G |
| description | Angiogenesis is an essential process for the expansion of multiple myeloma (MM), in which many angiogenic factors participate. Endoglin (CD105) is a transforming growth factor‐β co‐receptor, being mainly expressed in angiogenic endothelial cells and has been used as a marker of tumor angiogenesis, having prognostic potential. The aim of the study was to evaluate serum levels of soluble CD105 (sCD105) in MM patients, both during diagnosis and after effective conventional chemotherapy, in the plateau phase, and to correlate them with the clinical stage of the disease, as well as with the known angiogenic factors vascular endothelial growth factor, angiogenin and interleukin‐18 (IL‐18). Serum levels of the aforementioned factors were measured, by enzyme‐linked immunosorbent assay, in 56 newly diagnosed MM patients, in 35 of them who entered plateau phase and in 24 healthy controls. Bone marrow aspirations were also performed in all patients to determine plasma cell infiltration. All measured cytokines were higher in MM patients compared with controls and with advancing disease stage (p |
| doi_str_mv | 10.1002/hon.2044 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1668264472</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1504458171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3924-fe0bc4c6bca69776a7c7f8c486454e27d826bd4319bbe718bf94e1b940c08d2d3</originalsourceid><addsrcrecordid>eNqF0UFvFCEYBmBiNHatJv4Cw9HLtMAwMBx1W3ebNG1iNB4JA9-M2BkYYba6F3-7tF3ryXgg34GHN194EXpNyQklhJ1-jeGEEc6foBUlSlWUCPUUrQiTbUVYzY7Qi5y_EVLuSPscHbG6kYK2fIV-nU-QBh8GnOIIGcceQ3BxGH04XZ9R0mATXDmDjwMEb7HdL_HGh0L7mLDzGUwG7OAWxjhPEJb7B3OKQ4KcfQzYBzztxsXPI-BpX9hk8GwWX2x-iZ71Zszw6jCP0ecP55_W2-ryenOxfndZ2VoxXvVAOsut6KwRSkphpJV9a3kreMOBSdcy0TleU9V1IGnb9YoD7RQnlrSOufoYvX3ILYt930Fe9OSzhXE0AeIuaypEieBcsv_Tpnx001JJ_1KbYs4Jej0nP5m015Tou2J0KUbfFVPom0PqrpvAPcI_TRRQPYAffoT9P4P09vrqEHjwPi_w89GbdKOFrGWjv1xt9Ia8_3gmt0qv699IAqd8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504458171</pqid></control><display><type>article</type><title>Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients</title><source>Wiley</source><creator>Pappa, CA ; Alexandrakis, MG ; Boula, A ; Psarakis, FE ; Kolovou, A ; Bantouna, V ; Stavroulaki, E ; Tsirakis, G</creator><creatorcontrib>Pappa, CA ; Alexandrakis, MG ; Boula, A ; Psarakis, FE ; Kolovou, A ; Bantouna, V ; Stavroulaki, E ; Tsirakis, G</creatorcontrib><description>Angiogenesis is an essential process for the expansion of multiple myeloma (MM), in which many angiogenic factors participate. Endoglin (CD105) is a transforming growth factor‐β co‐receptor, being mainly expressed in angiogenic endothelial cells and has been used as a marker of tumor angiogenesis, having prognostic potential. The aim of the study was to evaluate serum levels of soluble CD105 (sCD105) in MM patients, both during diagnosis and after effective conventional chemotherapy, in the plateau phase, and to correlate them with the clinical stage of the disease, as well as with the known angiogenic factors vascular endothelial growth factor, angiogenin and interleukin‐18 (IL‐18). Serum levels of the aforementioned factors were measured, by enzyme‐linked immunosorbent assay, in 56 newly diagnosed MM patients, in 35 of them who entered plateau phase and in 24 healthy controls. Bone marrow aspirations were also performed in all patients to determine plasma cell infiltration. All measured cytokines were higher in MM patients compared with controls and with advancing disease stage (p < 0.001 for all cases). Furthermore, the values of all factors decreased significantly in the plateau phase (p < 0.001 for all cases). Serum levels of sCD105 correlated with the other angiogenic cytokines, whereas only serum levels of angiogenin had prognostic value for the survival. In conclusion, CD105 and the angiogenic cytokines vascular endothelial growth factor, angiogenin and IL‐18, seem to have emerging roles both in angiogenesis and tumor growth in MM. Copyright © 2013 John Wiley & Sons, Ltd.</description><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.2044</identifier><identifier>PMID: 23576184</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; angiogenesis ; Antigens, CD - blood ; Antigens, CD - physiology ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bone Marrow - pathology ; cytokines ; Disease Progression ; Endoglin ; Female ; Humans ; Interleukin-18 - blood ; Kaplan-Meier Estimate ; Male ; Middle Aged ; multiple myeloma ; Multiple Myeloma - blood ; Multiple Myeloma - drug therapy ; Multiple Myeloma - pathology ; Multiple Myeloma - physiopathology ; Neoplasm Proteins - blood ; Neovascularization, Pathologic - physiopathology ; Prognosis ; Receptors, Cell Surface - blood ; Receptors, Cell Surface - physiology ; Ribonuclease, Pancreatic - blood ; Vascular Endothelial Growth Factor A - blood</subject><ispartof>Hematological oncology, 2013-12, Vol.31 (4), p.201-205</ispartof><rights>Copyright © 2013 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3924-fe0bc4c6bca69776a7c7f8c486454e27d826bd4319bbe718bf94e1b940c08d2d3</citedby><cites>FETCH-LOGICAL-c3924-fe0bc4c6bca69776a7c7f8c486454e27d826bd4319bbe718bf94e1b940c08d2d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23576184$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pappa, CA</creatorcontrib><creatorcontrib>Alexandrakis, MG</creatorcontrib><creatorcontrib>Boula, A</creatorcontrib><creatorcontrib>Psarakis, FE</creatorcontrib><creatorcontrib>Kolovou, A</creatorcontrib><creatorcontrib>Bantouna, V</creatorcontrib><creatorcontrib>Stavroulaki, E</creatorcontrib><creatorcontrib>Tsirakis, G</creatorcontrib><title>Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients</title><title>Hematological oncology</title><addtitle>Hematol Oncol</addtitle><description>Angiogenesis is an essential process for the expansion of multiple myeloma (MM), in which many angiogenic factors participate. Endoglin (CD105) is a transforming growth factor‐β co‐receptor, being mainly expressed in angiogenic endothelial cells and has been used as a marker of tumor angiogenesis, having prognostic potential. The aim of the study was to evaluate serum levels of soluble CD105 (sCD105) in MM patients, both during diagnosis and after effective conventional chemotherapy, in the plateau phase, and to correlate them with the clinical stage of the disease, as well as with the known angiogenic factors vascular endothelial growth factor, angiogenin and interleukin‐18 (IL‐18). Serum levels of the aforementioned factors were measured, by enzyme‐linked immunosorbent assay, in 56 newly diagnosed MM patients, in 35 of them who entered plateau phase and in 24 healthy controls. Bone marrow aspirations were also performed in all patients to determine plasma cell infiltration. All measured cytokines were higher in MM patients compared with controls and with advancing disease stage (p < 0.001 for all cases). Furthermore, the values of all factors decreased significantly in the plateau phase (p < 0.001 for all cases). Serum levels of sCD105 correlated with the other angiogenic cytokines, whereas only serum levels of angiogenin had prognostic value for the survival. In conclusion, CD105 and the angiogenic cytokines vascular endothelial growth factor, angiogenin and IL‐18, seem to have emerging roles both in angiogenesis and tumor growth in MM. Copyright © 2013 John Wiley & Sons, Ltd.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>angiogenesis</subject><subject>Antigens, CD - blood</subject><subject>Antigens, CD - physiology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bone Marrow - pathology</subject><subject>cytokines</subject><subject>Disease Progression</subject><subject>Endoglin</subject><subject>Female</subject><subject>Humans</subject><subject>Interleukin-18 - blood</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>multiple myeloma</subject><subject>Multiple Myeloma - blood</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - pathology</subject><subject>Multiple Myeloma - physiopathology</subject><subject>Neoplasm Proteins - blood</subject><subject>Neovascularization, Pathologic - physiopathology</subject><subject>Prognosis</subject><subject>Receptors, Cell Surface - blood</subject><subject>Receptors, Cell Surface - physiology</subject><subject>Ribonuclease, Pancreatic - blood</subject><subject>Vascular Endothelial Growth Factor A - blood</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqF0UFvFCEYBmBiNHatJv4Cw9HLtMAwMBx1W3ebNG1iNB4JA9-M2BkYYba6F3-7tF3ryXgg34GHN194EXpNyQklhJ1-jeGEEc6foBUlSlWUCPUUrQiTbUVYzY7Qi5y_EVLuSPscHbG6kYK2fIV-nU-QBh8GnOIIGcceQ3BxGH04XZ9R0mATXDmDjwMEb7HdL_HGh0L7mLDzGUwG7OAWxjhPEJb7B3OKQ4KcfQzYBzztxsXPI-BpX9hk8GwWX2x-iZ71Zszw6jCP0ecP55_W2-ryenOxfndZ2VoxXvVAOsut6KwRSkphpJV9a3kreMOBSdcy0TleU9V1IGnb9YoD7RQnlrSOufoYvX3ILYt930Fe9OSzhXE0AeIuaypEieBcsv_Tpnx001JJ_1KbYs4Jej0nP5m015Tou2J0KUbfFVPom0PqrpvAPcI_TRRQPYAffoT9P4P09vrqEHjwPi_w89GbdKOFrGWjv1xt9Ia8_3gmt0qv699IAqd8</recordid><startdate>201312</startdate><enddate>201312</enddate><creator>Pappa, CA</creator><creator>Alexandrakis, MG</creator><creator>Boula, A</creator><creator>Psarakis, FE</creator><creator>Kolovou, A</creator><creator>Bantouna, V</creator><creator>Stavroulaki, E</creator><creator>Tsirakis, G</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201312</creationdate><title>Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients</title><author>Pappa, CA ; Alexandrakis, MG ; Boula, A ; Psarakis, FE ; Kolovou, A ; Bantouna, V ; Stavroulaki, E ; Tsirakis, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3924-fe0bc4c6bca69776a7c7f8c486454e27d826bd4319bbe718bf94e1b940c08d2d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>angiogenesis</topic><topic>Antigens, CD - blood</topic><topic>Antigens, CD - physiology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bone Marrow - pathology</topic><topic>cytokines</topic><topic>Disease Progression</topic><topic>Endoglin</topic><topic>Female</topic><topic>Humans</topic><topic>Interleukin-18 - blood</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>multiple myeloma</topic><topic>Multiple Myeloma - blood</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - pathology</topic><topic>Multiple Myeloma - physiopathology</topic><topic>Neoplasm Proteins - blood</topic><topic>Neovascularization, Pathologic - physiopathology</topic><topic>Prognosis</topic><topic>Receptors, Cell Surface - blood</topic><topic>Receptors, Cell Surface - physiology</topic><topic>Ribonuclease, Pancreatic - blood</topic><topic>Vascular Endothelial Growth Factor A - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pappa, CA</creatorcontrib><creatorcontrib>Alexandrakis, MG</creatorcontrib><creatorcontrib>Boula, A</creatorcontrib><creatorcontrib>Psarakis, FE</creatorcontrib><creatorcontrib>Kolovou, A</creatorcontrib><creatorcontrib>Bantouna, V</creatorcontrib><creatorcontrib>Stavroulaki, E</creatorcontrib><creatorcontrib>Tsirakis, G</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pappa, CA</au><au>Alexandrakis, MG</au><au>Boula, A</au><au>Psarakis, FE</au><au>Kolovou, A</au><au>Bantouna, V</au><au>Stavroulaki, E</au><au>Tsirakis, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients</atitle><jtitle>Hematological oncology</jtitle><addtitle>Hematol Oncol</addtitle><date>2013-12</date><risdate>2013</risdate><volume>31</volume><issue>4</issue><spage>201</spage><epage>205</epage><pages>201-205</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><abstract>Angiogenesis is an essential process for the expansion of multiple myeloma (MM), in which many angiogenic factors participate. Endoglin (CD105) is a transforming growth factor‐β co‐receptor, being mainly expressed in angiogenic endothelial cells and has been used as a marker of tumor angiogenesis, having prognostic potential. The aim of the study was to evaluate serum levels of soluble CD105 (sCD105) in MM patients, both during diagnosis and after effective conventional chemotherapy, in the plateau phase, and to correlate them with the clinical stage of the disease, as well as with the known angiogenic factors vascular endothelial growth factor, angiogenin and interleukin‐18 (IL‐18). Serum levels of the aforementioned factors were measured, by enzyme‐linked immunosorbent assay, in 56 newly diagnosed MM patients, in 35 of them who entered plateau phase and in 24 healthy controls. Bone marrow aspirations were also performed in all patients to determine plasma cell infiltration. All measured cytokines were higher in MM patients compared with controls and with advancing disease stage (p < 0.001 for all cases). Furthermore, the values of all factors decreased significantly in the plateau phase (p < 0.001 for all cases). Serum levels of sCD105 correlated with the other angiogenic cytokines, whereas only serum levels of angiogenin had prognostic value for the survival. In conclusion, CD105 and the angiogenic cytokines vascular endothelial growth factor, angiogenin and IL‐18, seem to have emerging roles both in angiogenesis and tumor growth in MM. Copyright © 2013 John Wiley & Sons, Ltd.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>23576184</pmid><doi>10.1002/hon.2044</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0232 |
| ispartof | Hematological oncology, 2013-12, Vol.31 (4), p.201-205 |
| issn | 0278-0232 1099-1069 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1668264472 |
| source | Wiley |
| subjects | Adult Aged Aged, 80 and over angiogenesis Antigens, CD - blood Antigens, CD - physiology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bone Marrow - pathology cytokines Disease Progression Endoglin Female Humans Interleukin-18 - blood Kaplan-Meier Estimate Male Middle Aged multiple myeloma Multiple Myeloma - blood Multiple Myeloma - drug therapy Multiple Myeloma - pathology Multiple Myeloma - physiopathology Neoplasm Proteins - blood Neovascularization, Pathologic - physiopathology Prognosis Receptors, Cell Surface - blood Receptors, Cell Surface - physiology Ribonuclease, Pancreatic - blood Vascular Endothelial Growth Factor A - blood |
| title | Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T22%3A36%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Emerging%20roles%20of%20endoglin/CD105%20and%20angiogenic%20cytokines%20for%20disease%20development%20and%20progression%20in%20multiple%20myeloma%20patients&rft.jtitle=Hematological%20oncology&rft.au=Pappa,%20CA&rft.date=2013-12&rft.volume=31&rft.issue=4&rft.spage=201&rft.epage=205&rft.pages=201-205&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.2044&rft_dat=%3Cproquest_cross%3E1504458171%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3924-fe0bc4c6bca69776a7c7f8c486454e27d826bd4319bbe718bf94e1b940c08d2d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1504458171&rft_id=info:pmid/23576184&rfr_iscdi=true |